Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenhui Deng

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Clinical Pharmacology in Drug Development|July 16, 2024
Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced TumorsFang Yang, Yongying Lu, Lihui Bai, et al.
Rheumatology (Oxford, England)|August 24, 2018
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority studyYoshiya Tanaka, Naonobu Sugiyama, Shigeyuki Toyoizumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Clinical Pharmacology in Drug Development|July 16, 2024
Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced TumorsFang Yang, Yongying Lu, Lihui Bai, et al.
Rheumatology (Oxford, England)|August 24, 2018
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority studyYoshiya Tanaka, Naonobu Sugiyama, Shigeyuki Toyoizumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Pageof 3